Date: 2011-12-05
Type of information: Commercialisation agreement
Compound: Esmya® (ulipristal acetate)
Company: HRA Pharma (France) Gedeon Richter (Hungary)
Therapeutic area: Gynecology - Women's health
Type agreement: distribution
commercialisation
Action mechanism:
Disease: uterine fibroids (myoma)
Details: HRA Pharma and Gedeon Richter Plc. have announced that Richter has been recently awarded the exclusive distribution and marketing rights for the innovative product, Esmya® (ulipristal acetate), indicated for the treatment of uterine fibroids (myoma), in Russia, other CIS republics and China.
This new arrangement follows the news that on 7th October 2010, Richter acquired PregLem, a privately held Swiss pharmaceutical company specialising in the treatment of benign gynaecological conditions. As a result of the acquisition, Gedeon Richter Plc. procured the distribution and marketing rights that HRA Pharma had granted PregLem for Esmya™, the lead product in PregLem’s portfolio, across the European Union and in North America.
HRA Pharma still retains the licensing rights for ulipristal acetate in the treatment of benign gynaecological conditions across the rest of the World. HRA is keen to bring the product to market in Asia/Pacific, Latin America and Africa and is actively seeking new partners with a commitment to women’s health with the aim of developing its global footprint.
Financial terms:
Latest news:
